Ontology highlight
ABSTRACT: Background
Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments.Objective
Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient subgroups from DECIDE.Methods
Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on a modified Multiple Sclerosis Functional Composite (MSFCS) where 3-Second Paced Auditory Serial Addition Test was replaced by Symbol Digit Modalities Test, and proportion of patients with clinically meaningful worsening in 29-Item Multiple Sclerosis Impact Scale physical impact subscale (MSIS-29 PHYS) score from baseline to week 96 were examined in the overall population and subgroups defined by baseline demographic/disease characteristics.Results
Daclizumab beta significantly reduced risk of 24-week CDP (hazard ratio (HR), 0.73; 95% confidence interval (95% CI), 0.55-0.98), risk of 24-week sustained MSFCS progression (HR, 0.80; 95% CI, 0.67-0.95), and odds of clinically meaningful worsening in MSIS-29 PHYS (odds ratio, 0.76; 95% CI, 0.60-0.95) versus IM interferon beta-1a. Point estimates showed trends favoring daclizumab beta over IM interferon beta-1a across several patient subgroups for all three outcome measures.Conclusion
Daclizumab beta showed consistent benefit versus IM interferon beta-1a across measures assessing patient disability/function and across a range of clinical baseline characteristics in patients with relapsing-remitting MS.
SUBMITTER: Cohan S
PROVIDER: S-EPMC6282160 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
Cohan Stanley S Kappos Ludwig L Giovannoni Gavin G Wiendl Heinz H Selmaj Krzysztof K Havrdová Eva Kubala EK Rose John J Greenberg Steven S Phillips Glenn G Ma Wei W Wang Ping P Lima Gabriel G Sabatella Guido G
Multiple sclerosis (Houndmills, Basingstoke, England) 20171006 14
<h4>Background</h4>Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments.<h4>Objective</h4>Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient subgroups from DECIDE.<h4>Methods</h4>Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on a modified Multiple Sclerosis Functional Composite (MSFCS) wher ...[more]